SEC Form 4 · accession 0001104659-19-011636
MARINUS PHARMACEUTICALS INC · MRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Braunstein
Officer — Executive Chairman · Director
Period of report
Feb 26, 2019
Accepted (ET)
Feb 28, 2019 · 6:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $3.96 | Feb 26, 2019 | A | 240,000 | A | — | Feb 26, 2029 | Common Stock | 240,000 | 240,000 | D |
Explanation of responses
- F1Options to purchase shares of common stock vest in 24 equal monthly installments of 10,000 shares each, commencing on 2/26/19 and continuing until the Reporting Person is terminated under the terms of the Reporting Person's employment agreement with the Issuer, at which time all unvested options to purchase common stock will be forfeited. Vested options will expire on the earlier of the one-year anniversary after Executive's continuous service on the Board of Directors terminates or ten years after the grant date.